Juno Therapeutics, Inc. (NASDAQ:JUNO) Files An 8-K Entry into a Material Definitive Agreement


Juno Therapeutics, Inc. (NASDAQ:JUNO) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.

(d) Exhibits

* The schedules to the Merger Agreement have been omitted from this filing to Item 601(b)(2) of Regulation S-K. Juno will furnish copies of such schedules to the SEC upon request; provided, however, that Juno may request confidential treatment to Rule 24b-2 of the Exchange Act for any schedule so furnished.

Juno Therapeutics, Inc. Exhibit
EX-2.1 2 d521429dex21.htm EX-2.1 EX-2.1 Exhibit 2.1 EXECUTION VERSION       AGREEMENT AND PLAN OF MERGER among: JUNO THERAPEUTICS,…
To view the full exhibit click here

About Juno Therapeutics, Inc. (NASDAQ:JUNO)

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Its other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171) and JCAR020: MUC-16/IL-12. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.